Verona Pharma PLC Alpha and Beta Analysis

VRNADelisted Stock  USD 86.00  2.00  2.38%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Verona Pharma PLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Verona Pharma over a specified time horizon. Remember, high Verona Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Verona Pharma's market risk premium analysis include:
Beta
0.0854
Alpha
(0.29)
Risk
2.75
Sharpe Ratio
0.11
Expected Return
0.29
Please note that although Verona Pharma alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Verona Pharma did 0.29  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Verona Pharma PLC stock's relative risk over its benchmark. Verona Pharma PLC has a beta of 0.09  . As returns on the market increase, Verona Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Verona Pharma is expected to be smaller as well. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Verona Pharma Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Verona Pharma market risk premium is the additional return an investor will receive from holding Verona Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Verona Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Verona Pharma's performance over market.
α-0.29   β0.09

Verona Pharma Fundamentals Vs Peers

Comparing Verona Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Verona Pharma's direct or indirect competition across all of the common fundamentals between Verona Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Verona Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Verona Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Verona Pharma by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Verona Pharma to competition
FundamentalsVerona PharmaPeer Average
Return On Equity-0.36-0.31
Return On Asset-0.0668-0.14
Profit Margin(0.37) %(1.27) %
Operating Margin0.13 %(5.51) %
Current Valuation8.99 B16.62 B
Shares Outstanding84.98 M571.82 M
Shares Owned By Insiders4.88 %10.09 %

Verona Pharma Opportunities

Verona Pharma Return and Market Media

The Stock received a lot of media exposure during the period.
 Price Growth (%)  
       Timeline  
1
Verona Pharma Assessing Valuation After Recent Share Price Movement
09/09/2025
2
Why Verona Pharma plc stock attracts HNW investors - Quarterly Earnings Report Safe Capital Growth Tips - newser.com
09/29/2025
3
Verona Pharma plc s Shareholders Authorizes the 10 Billion Acquisition of Verona Pharma plc Nasdaq Trading to Suspend
10/08/2025
4
Merck Completes 10B Acquisition of Verona Pharma, Adds COPD Drug Ohtuvayre
10/13/2025
5
Will Verona Pharma plc stock outperform energy sector in 2025 - Weekly Loss Report Free Expert Verified Stock Movement Alerts - nchmf.gov.vn
10/20/2025
6
Using data models to predict Verona Pharma plc Depositary Receipt stock movement - Trade Volume Report Risk Adjusted Swing Trade Ideas - newser.com
10/24/2025
7
JNJ vs. MRK Which Blue-Chip Pharma Stock Should Be in Your Portfolio
10/27/2025
8
Verona Pharma PLC American Depositary Share VRNA Shares Bought by Y Intercept Hong Kong Ltd
10/28/2025
9
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
10/30/2025
10
Can momentum traders help lift Verona Pharma plc Depositary Receipt - Market Performance Recap AI Driven Stock Price Forecasts - newser.com
11/04/2025

About Verona Pharma Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Verona or other delisted stocks. Alpha measures the amount that position in Verona Pharma PLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

Verona Pharma Upcoming Company Events

As portrayed in its financial statements, the presentation of Verona Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verona Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Verona Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Verona Pharma. Please utilize our Beneish M Score to check the likelihood of Verona Pharma's management manipulating its earnings.
5th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Verona Pharma

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Verona Stock

If you are still planning to invest in Verona Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Verona Pharma's history and understand the potential risks before investing.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments